Chembio Diagnostics, Inc. announced the appointment of Richard Eberly as its President and Chief Executive Officer effective March 16, 2020. Mr. Eberly also will be a director nominee for election at Chembio's 2020 Annual Meeting of Stockholders. Gail Page, a Chembio director who has served as Chembio's Interim CEO since early January 2020, will assume an active advisory role for ninety days to assist in the leadership transition.

Mr. Eberly was formerly a Managing Director at Solid Rock Principled Capital, where he was instrumental in developing strategy and optimizing operations for the firm. Prior to Solid Rock, Richard held various roles of increasing responsibility over 23 years at Meridian Biosciences Inc., ultimately serving as the company's President and Chief Commercial Officer. Meridian Bioscience is a life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.

Under his leadership the company successfully grew sales, improved operations and profitability, launched significant new product lines and completed several acquisitions. He began his career at Abbott Diagnostics.